Business
Result of Fundraising
Result of Fundraising.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \nRNS Number : 7442X Futura Medical PLC 23 December 2019 \n\n23 December 2019\n \nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, AUSTRALIA, THE REPUBLIC OF IRELAND, NEW ZEALAND OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. \nTHIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN FUTURA MEDICAL PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF FUTURA MEDICAL PLC.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014.\nUNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS ANNOUNCEMENT HAVE THE MEANING GIVEN TO THEM IN THE DEFINITIONS SECTION INCLUDED IN THE APPENDIX TO THE ANNOUNCEMENT MADE BY THE COMPANY ON 20 DECEMBER 2019.\n \n \nFutura Medical plc\n \n(\"Futura\" or the \"Company\")\n \nResult of Fundraising and Participation of a \nDirector and Substantial Shareholder in the Fundraising \n \nFutura, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology and focused on sexual health and pain confirms that, further to the announcement made on Friday, it has conditionally raised £3.25 million in aggregate before fees and expenses through a successful Subscription and PrimaryBid Offer at the Issue Price of 8 pence per share. \n \nThe £1.5 million PrimaryBid Offer was fully taken up. Due to high demand, the PrimaryBid Offer was oversubscribed and closed early.\n \nThe Company announces that existing institutional investor Lombard Odier has subscribed for a total of 21,875,000 Investor Subscription Shares (representing an aggregate investment of £1.75 million) and that the 18,750,000 PrimaryBid Shares which Lombard Odi...